WO2023083381A1 - 双特异性抗体-喜树碱类药物偶联物及其医药用途 - Google Patents

双特异性抗体-喜树碱类药物偶联物及其医药用途 Download PDF

Info

Publication number
WO2023083381A1
WO2023083381A1 PCT/CN2022/132027 CN2022132027W WO2023083381A1 WO 2023083381 A1 WO2023083381 A1 WO 2023083381A1 CN 2022132027 W CN2022132027 W CN 2022132027W WO 2023083381 A1 WO2023083381 A1 WO 2023083381A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
seq
substituted
pharmaceutically acceptable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/132027
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
朱义
万维李
于天姿
朱贵莉
张宜英
卓识
张勇
李刚锐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baili Bio Chengdu Pharmaceutical Co Ltd
Original Assignee
Baili Bio Chengdu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2024005831A priority Critical patent/MX2024005831A/es
Priority to EP22892173.0A priority patent/EP4434548A1/en
Priority to JP2024529137A priority patent/JP7767613B2/ja
Priority to PE2024001076A priority patent/PE20250759A1/es
Priority to CA3237844A priority patent/CA3237844A1/en
Priority to IL312694A priority patent/IL312694A/en
Priority to US18/710,044 priority patent/US20250059296A1/en
Priority to KR1020247019719A priority patent/KR20240101682A9/ko
Priority to AU2022386505A priority patent/AU2022386505A1/en
Application filed by Baili Bio Chengdu Pharmaceutical Co Ltd filed Critical Baili Bio Chengdu Pharmaceutical Co Ltd
Publication of WO2023083381A1 publication Critical patent/WO2023083381A1/zh
Priority to TW112128599A priority patent/TW202434301A/zh
Priority to CONC2024/0006160A priority patent/CO2024006160A2/es
Anticipated expiration legal-status Critical
Priority to US18/957,324 priority patent/US12577325B2/en
Priority to JP2025182282A priority patent/JP2026035591A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • the invention relates to the field of biopharmaceuticals, in particular to an antibody-drug conjugate formed by a bispecific antibody and a camptothecin drug, as well as a preparation method and application of the antibody-drug conjugate.
  • the invention also relates to linker-drug compounds that can be conjugated to Abs to form antibody-toxin conjugates.
  • EGFR Epidermal Growth Factor Receptor
  • HER3 and ErbB3 are both receptor protein tyrosine kinases and belong to the epidermal group of receptor protein tyrosine kinases Growth factor receptor (EGFR) subfamily, which includes EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4).
  • Epidermal growth factor receptor is a glycoprotein with a molecular weight of 170kDa, which penetrates the cell membrane and is activated by binding to a ligand.
  • EGFR converts from a monomer to a self-dimer or forms a heterodimer with other human epidermal growth factor receptor family members. After dimer formation, it activates the intracellular kinase pathway, guides the phosphorylation of downstream pathways, including MAPK, Akt and JNK pathways, and induces cell proliferation.
  • MAPK kinase pathway
  • Akt Akt
  • JNK pathways phosphorylation of downstream pathways
  • EGFR can promote tumor formation.
  • the EGFR signaling pathway is activated, and the expression level of EGFR is positively correlated with the stage of cancer development.
  • EGFR due to the discovery of secondary mutations of EGFR under drug pressure, more and more studies have used EGFR as a biomarker of tumor drug resistance.
  • Epidermal growth factor receptor 3 (Her3 or ErbB3) also has a typical epidermal growth factor receptor structure, but Her3 lacks an intracellular protein tyrosine kinase domain and thus cannot autophosphorylate. Her3 can bind to ligand proteins and promote its heterodimerization with other human epidermal growth factor receptor family members to activate receptor-mediated signal transduction pathways, which not only serve as a means of signal diversification, but also play a role in signal amplification. speed up tumor progression. Heregulins (glial cell growth factor, Neudifferentiation factor) can activate intracellular kinase-dependent multi-step signaling pathway responses after binding to transmembrane receptors HER3 and HER4.
  • Heregulins glial cell growth factor, Neudifferentiation factor
  • HER3 Downregulation of this signaling pathway often leads to Alzheimer's disease, heart failure, atherosclerosis and cancer, among others.
  • Up-regulation of HER3 can promote tumorigenesis and growth by interacting with receptor tyrosine kinases (RTKs).
  • RTKs receptor tyrosine kinases
  • HER3 is a heterodimeric molecular chaperone of other EGFR family members, it has the possibility to regulate the drug resistance of cancer cells mediated by EGFR/HER2 signaling pathway.
  • EGFR and Her3 are closely related to the occurrence of various tumors. Both EGFR and Her3 have been shown to drive tumor development in solid tumors such as breast cancer, lung cancer, gastric cancer, and pancreatic cancer. Several studies have shown that the high expression of Her3 is related to the clinical failure of EGFR antibodies and inhibitors. In clinical practice, there are already several combined drug treatments targeting EGFR and Her3 in progress.
  • Bispecific monoclonal antibody refers to a monoclonal antibody molecule with two different antigen recognition sequences, which can bind to two antigenic epitope protein molecules, so as to achieve, for example, the ability to mediate the killing of tumor cells by immune cells and mediate less toxicity
  • anti-tumor mechanisms such as the killing of tumor cells by molecules or blocking the signaling pathways that promote tumor growth.
  • bispecific monoclonal antibodies The development of bispecific monoclonal antibodies is mainly based on the consideration that multiple mediators are involved in the pathogenesis of tumors through specific or overlapping mechanisms. Blocking multiple targets at the same time will result in better treatment than inhibiting a single target. Effect, at the same time, the role of multiple targets makes the probability of drug resistance greatly reduced.
  • two bispecific antibodies, Catumaxomab and Blinatumomab have been approved for marketing in the United States, and more than 50 bispecific antibody molecules are undergoing clinical trials.
  • Antibody-drug conjugates are molecules with specific targeting and killing effects obtained by linking small molecule toxins with cell-killing effects to antibodies, and are mainly used for the treatment of tumors and other diseases. treat. Antibodies used in antibody-drug conjugates can specifically bind to proteins on the surface of tumor cells, so they have tumor specificity and potential that cannot be achieved by traditional drugs.
  • ADC drugs have been approved for marketing in the world, and hundreds of projects are undergoing clinical trials. However, the vast majority of ADC projects currently on the market or in clinical practice are aimed at one target, and cannot achieve the synergistic advantages of dual-target therapy.
  • the inventors disclose a bispecific antibody-drug conjugate and a preparation method thereof, a pharmaceutical composition comprising the conjugate, and the conjugate or drug combination use of things.
  • the invention also relates to linker-drug compounds that can be conjugated to bispecific antibodies to form antibody-toxin conjugates.
  • the first aspect of the present invention discloses a ligand-camptothecin derivative conjugate shown in general formula I or a pharmaceutically acceptable salt or solvate thereof;
  • Ab is a bispecific antibody or an antigen-binding fragment thereof that simultaneously targets two different epitopes or targets;
  • L is non-limitingly selected from:
  • L2 has the structure shown in formula A below,
  • Y is a scaffold, selected from C1-C6 alkyl, substituted C1-C6 alkyl or C3-C8 cycloalkyl; preferably Y is C1-C6 alkyl; Ac is a hydrophilic structural unit; the 2nd carbon connected to Y Absolute chirality with R configuration or S configuration;
  • L3 is present or absent, when present, L3 is selected from the PEG hydrophilic unit: o an integer selected from 1-10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), preferably an integer of 2-8;
  • L4 is an enzyme cutting unit
  • L 5 is a connection unit
  • the No. 1 chiral carbon atom connected to N in formula I has absolute chirality of R configuration or S configuration;
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R 1 is selected from C1-C6 alkyl
  • R2 is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from hydrogen atom, halogen or C1-C6 alkyl
  • R is selected from halogen
  • X is selected from -C(O)-CR a R b -(CR 3 R 4 ) m -O-, -C(O)-CR a R b -(CR 3 R 4 ) m -NH- or -C( O)-CR a R b -(CR 3 R 4 ) m -S-;
  • X is selected from -C(O)-CR a R b -(CR 3 R 4 ) m -O-;
  • R a and R b are each independently selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 Cycloalkyl C1-C6 alkyl, C6-C10 aryl C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6 -C10 aryl, substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R a and R b are each independently selected from hydrogen atom, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl or C6-C10 aryl C1-C6 alkyl ;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group C1-C6 alkyl group, a 3-7 membered heterocyclic group, or a substituted 3-7 membered heterocyclic group;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group;
  • R 3 and R 4 are the same or different, and are independently hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, deuterated C1-C6 alkyl, C1-C6 alkoxy , hydroxy, amino, cyano, nitro, hydroxy C1-C6 alkyl, C3-C8 cycloalkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group;
  • R 3 and R 4 are independently a hydrogen atom or a C1-C6 alkyl group
  • R 3 , R 4 and the carbon atoms connected to them constitute C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, 3-7 membered heterocyclic group, or substituted 3-7 membered heterocyclic group;
  • n is selected from an integer of 1-10 (such as 1, 2, 3, 4, 5, 6, 7 , 8, 9 or 10).
  • a ligand-camptothecin derivative conjugate as shown in general formula I or a pharmaceutically acceptable salt or solvate thereof is disclosed, wherein Ab is A bispecific antibody or an antigen-binding fragment thereof that simultaneously targets two different epitopes or targets, preferably a bispecific antibody or an antigen-binding fragment thereof that simultaneously targets EGFR and HER3.
  • a ligand-camptothecin derivative conjugate as shown in general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the antibody comprises: an IgG1 heavy chain, a ⁇ light chain, and a single-chain Fv (scFv) domain; wherein the single-chain Fv (scFv) domain forms a construct with an IgG1 heavy chain or a ⁇ light chain; wherein the IgG1 heavy chain and The kappa light chain forms the IgG portion with binding specificity for EGFR; the scFv domain has binding specificity for HER3, and the scFv domain is passed through a linker (e.g., with amino acids (gly-gly-gly-gly-ser)n).
  • a linker e.g., with amino acids (gly-gly-gly-gly-ser)n.
  • n is an integer of at least 1, preferably n is an integer of 1 to 10
  • n is an integer of at least 1 heavy chain or the C-terminal or N-terminal of the kappa light chain
  • a single Chain Fv domains have a structural order of N-terminus-heavy chain variable region-linker-light chain variable region-C-terminus or N-terminus-light chain variable region-linker-heavy chain variable region-C-terminus
  • the linker consists of the amino acid sequence of (gly-gly-gly-gly-ser)m, wherein m is an integer of at least 3, preferably m is 3, 4, 5, or 6).
  • a ligand-camptothecin derivative conjugate as shown in general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the ⁇ light chain of the antibody comprises CDRs shown in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and the IgG1 heavy chain comprises SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO The CDR shown in: 31, and the single-chain Fv (scFv) domain comprises the heavy chain variable region CDR shown in SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, such as SEQ ID NO: 35.
  • the light chain variable region CDRs shown in SEQ ID NO: 36 and SEQ ID NO: 37 is disclosed, characterized in that Ab
  • the ⁇ light chain of the antibody comprises CDRs shown in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and the IgG1 heavy chain comprises SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO The
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 28, the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 38, and the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 39
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:40 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 28
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 38
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 39
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:40 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in S
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain amino acid sequence of the antibody is SEQ ID NO:2
  • the amino acid sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO:4.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain nucleic acid coding sequence of the antibody is SEQ ID NO: 1
  • the nucleic acid coding sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO: 3.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the ⁇ light chain of the antibody includes CDRs shown in SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, and the IgG1 heavy chain includes SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO:
  • the CDR shown in 47, and the single chain Fv (scFv) domain comprises the heavy chain variable region CDR shown in SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, such as SEQ ID NO: 35 , SEQ ID NO: 36, the light chain variable region CDR shown in SEQ ID NO: 37.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 44
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 48
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 39
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:40 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 44
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 48
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 39
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain amino acid sequence of the antibody is SEQ ID NO: 6, and the amino acid sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO: 8.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain nucleic acid coding sequence of the antibody is SEQ ID NO: 5
  • the nucleic acid coding sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO: 7.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 49
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 52
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 50
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:51 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 49
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 52
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 50
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:51 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the amino acid sequence of the heavy chain of the antibody is SEQ ID NO: 12
  • the amino acid sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 10.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the nucleic acid coding sequence of the heavy chain of the antibody is SEQ ID NO: 11, and the nucleic acid coding sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 9.
  • the ligand-camptothecin derivative conjugate shown in general formula I is disclosed, or a pharmaceutically acceptable salt or solvate thereof, characterized in that Ab
  • the light chain amino acid sequence of the antibody is SEQ ID NO: 14, and the amino acid sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO: 16.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain nucleic acid coding sequence of the antibody is SEQ ID NO: 13
  • the nucleic acid coding sequence of the antibody heavy chain and single-chain Fv (scFv) domain construct is SEQ ID NO: 15.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the amino acid sequence of the heavy chain of the antibody is SEQ ID NO: 20
  • the amino acid sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 18.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the nucleic acid coding sequence of the heavy chain of the antibody is SEQ ID NO: 19, and the nucleic acid coding sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 17.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 53
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 54
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 50
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:51 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown in SEQ ID NO: 53
  • the IgG1 heavy chain comprises the variable region as shown in SEQ ID NO: 54
  • the single chain Fv (scFv) domain comprises the variable region as shown in SEQ ID NO: 50
  • the heavy chain variable region shown and the light chain variable region shown as SEQ ID NO:51 is disclosed, characterized in that Ab
  • the light chain of the antibody comprises the variable region as shown
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the amino acid sequence of the heavy chain of the antibody is SEQ ID NO: 24, and the amino acid sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 22.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the nucleic acid coding sequence of the heavy chain of the antibody is SEQ ID NO: 23, and the nucleic acid coding sequence of the construct of the antibody light chain and single-chain Fv (scFv) domain is SEQ ID NO: 21.
  • a ligand-camptothecin derivative conjugate represented by general formula I, or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ab
  • the antibody comprises: two IgGl heavy chains; two kappa light chains; and two single-chain Fv (scFv) domains.
  • a ligand-camptothecin derivative conjugate as shown in general formula I or a pharmaceutically acceptable salt or solvate thereof is disclosed, wherein the X is non-limitingly selected from the following structures or isomers thereof:
  • left wavy line is connected with the camptothecin derivative part, and the right wavy line is connected with L5 .
  • a ligand-camptothecin derivative conjugate shown in general formula I or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: L 4 non-limitingly selected from peptide residues consisting of amino acids,
  • the amino acid is further selected from deuterium atom, halogen, hydroxyl, cyano, amino, nitro, carboxyl, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy and C3 -C8 cycloalkyl or substituted by one or more substituents in C3-C8 cycloalkyl;
  • the peptide residue is composed of one, two or more selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline ( C), peptide residues formed from amino acids in serine (S), glutamic acid (E) or aspartic acid (D);
  • the peptide residues are tetrapeptide residues consisting of glycine (G)-glycine (G)-phenylalanine (F)-glycine (G).
  • the peptide residue is -GGFG-.
  • a ligand-camptothecin derivative conjugate shown in general formula I or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that:
  • L 5 is non-limitingly selected from -NR 5 (CR 6 R 7 ) q - or a chemical bond, q is selected from an integer of 0-6 (such as 0, 1, 2, 3,
  • R 5 , R 6 and R 7 are the same or different, and are independently selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 Cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl , Substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R 5 , R 6 and R 7 are each independently selected from a hydrogen atom or a C1-C6 alkyl group
  • R 5 , R 6 and R 7 are each independently selected from hydrogen atoms.
  • L is non-limitingly selected from:
  • a ligand-camptothecin derivative conjugate as shown in general formula I or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: the The linking unit -L 1 -L 2 -L 3 -L 4 -L 5 - is non-limitingly selected from the following structures;
  • R 5 , R 6 and R 7 are the same or different, and are independently selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 Cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl , Substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R 5 , R 6 and R 7 are each independently selected from a hydrogen atom or a C1-C6 alkyl group
  • R 5 , R 6 and R 7 are each independently selected from a hydrogen atom
  • the No. 2 carbon atom connected to N has absolute chirality of R configuration or S configuration
  • the wavy line on the left is connected to the antibody or its antigen-binding fragment part, and the wavy line on the right is connected to X;
  • o is an integer selected from 1-10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the second aspect of the present invention discloses a ligand-camptothecin derivative conjugate represented by general formula II, or a pharmaceutically acceptable salt or solvate thereof;
  • Ab is a bispecific antibody or an antigen-binding fragment thereof targeting both EGFR and HER3;
  • L 1 is a linking unit connected to Ab, non-limitingly selected from:
  • L 1 is preferably
  • L 1 is preferably
  • L 3 exists or does not exist, when L 3 exists, L 3 is selected from o an integer selected from 1-10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), preferably an integer of 2-8;
  • the 1-, 2-, and 3-position chiral carbon atoms have two chiral configurations: R absolute configuration or S absolute configuration;
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R 1 is selected from C1-C6 alkyl
  • R2 is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from hydrogen atom, halogen or C1-C6 alkyl
  • R is selected from halogen
  • X is selected from -C(O)-CR a R b -(CR 3 R 4 ) m -O-, -C(O)-CR a R b -(CR 3 R 4 ) m -NH- or -C( O)-CR a R b -(CR 3 R 4 ) m -S-;
  • X is selected from -C(O)-CR a R b -(CR 3 R 4 ) m -O-;
  • R a and R b are each independently selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 Cycloalkyl C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl, substituted C6-C10 aryl , 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R a and R b are each independently selected from hydrogen atom, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl or C6-C10 aryl C1-C6 alkyl ;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group C1-C6 alkyl group, a 3-7 membered heterocyclic group, or a substituted 3-7 membered heterocyclic group;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group;
  • R 3 and R 4 are the same or different, and are independently hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, deuterated C1-C6 alkyl, C1-C6 alkoxy , hydroxy, amino, cyano, nitro, hydroxy C1-C6 alkyl, C3-C8 cycloalkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group;
  • R 3 and R 4 are independently a hydrogen atom or a C1-C6 alkyl group
  • R 3 , R 4 and the carbon atoms connected to them constitute C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, 3-7 membered heterocyclic group, or substituted 3-7 membered heterocyclic group;
  • n is an integer selected from 0-4 (such as 0, 1, 2, 3 or 4), preferably 0, 1;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: Said Ac has the structure shown in the following formula B,
  • Z is non-limitingly selected from the group consisting of one or more of hydrophilic structure carboxyl, phosphoric acid, polyphosphoric acid, phosphorous acid, sulfonic acid, sulfinic acid or polyethylene glycol (PEG);
  • Z is selected from hydrophilic structure carboxyl, phosphoric acid or polyethylene glycol (PEG);
  • Y' is an optional bracket connecting the amino group and Z; preferably Y' is C1-C6 alkylene (such as methylene);
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: Said Ac is non-limitingly selected from glycine, (D/L) alanine, (D/L) leucine, (D/L) isoleucine, (D/L) valine, (D/L) L) Phenylalanine, (D/L) Proline, (D/L) Tryptophan, (D/L) Serine, (D/L) Tyrosine, (D/L) Cysteine , (D/L) cystine, (D/L) arginine, (D/L) histidine, (D/L) methionine, (D/L) asparagine, (D/L) gluten Aminoamide, (D/L) threonine, (D/L) aspartic acid, (D/L) glutamic acid, natural or unnatural
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: Said Ac is non-limitingly selected from glycine, phosphoric acid, (D/L) glutamic acid or polyethylene glycol hydrophilic structure.
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: described Have the structure shown in following formula d;
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from a hydrogen atom or a C1-C6 alkyl group
  • R 1 is selected from C1-C6 alkyl
  • R2 is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl group, carboxyl group, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl group, substituted C6-C10 aryl group, 5-10 membered heteroaryl group, substituted 5- 10-membered heteroaryl;
  • R is selected from hydrogen atom, halogen or C1-C6 alkyl
  • R is selected from halogen
  • R a and R b are each independently selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 Cycloalkyl C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl, substituted C6-C10 aryl , 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R a and R b are each independently selected from hydrogen atom, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl or C6-C10 aryl C1-C6 alkyl ;
  • R a and R b are each independently selected from a hydrogen atom, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl, C6-C10 aryl; preferably R a and R b are each independently selected from a hydrogen atom, methyl, ethyl, trifluoromethyl, cyclopropylmethyl, phenyl;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group C1-C6 alkyl group, a 3-7 membered heterocyclic group, or a substituted 3-7 membered heterocyclic group;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group (such as a C3-C5 cycloalkyl group);
  • the chiral carbon atom at position 1 has two chiral configurations: R absolute configuration or S absolute configuration;
  • n is selected from 0 or 1.
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that:
  • the above structural formula d is non-limitatively selected from the following compounds:
  • L may comprise a succinimide group.
  • the ligand-drug conjugate can be hydrolyzed under easy hydrolysis conditions, and the hydrolysis site is the succinimide group of the linking unit.
  • the ligand contains multiple linkers-drugs, the following situations may occur depending on the degree of hydrolysis:
  • the succinimide group is not hydrolyzed at all, that is, the succinimide group is in the form of a closed ring
  • the succinimide group is not completely hydrolyzed, that is, part of the succinimide group is in the closed ring form
  • the other part of the succinimide group is in the ring-opened form
  • the succinimide group is completely hydrolyzed, that is, the succinimide group is in the ring-opened form
  • succinimide-containing L 1s when multiple succinimide-containing L 1s are present in the ADC simultaneously (i.e., Ab is linked with multiple succinimide-containing drug-linkers), these succinimide
  • the groups may all be in closed ring form, partly in ring open form or all in ring open form.
  • the third aspect of the present invention discloses a linker-drug compound or a pharmaceutically acceptable salt or solvate thereof, characterized in that it has the structure shown in the following formula III,
  • R is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, deuterated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heteroaryl, substituted 5-10 membered heteroaryl;
  • R a is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 Alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heterocyclic group Aryl, substituted 5-10 membered heteroaryl;
  • R b is selected from hydrogen atom, deuterium atom, halogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 Alkyl, C1-C6 alkoxy C1-C6 alkyl, 3-7 membered heterocyclic group, substituted 3-7 membered heterocyclic group, C6-C10 aryl, substituted C6-C10 aryl, 5-10 membered heterocyclic group Aryl, substituted 5-10 membered heteroaryl;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group C1-C6 alkyl group, a 3-7 membered heterocyclic group, or a substituted 3-7 membered heterocyclic group;
  • R a and R b are each independently selected from a hydrogen atom, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl, C6-C10 aryl; preferably R a and R b are each independently selected from a hydrogen atom, methyl, ethyl, trifluoromethyl, cyclopropylmethyl, phenyl;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group C1-C6 alkyl group, a 3-7 membered heterocyclic group, or a substituted 3-7 membered heterocyclic group;
  • R a , R b and the carbon atoms connected to them form a C3-C8 cycloalkyl group (such as a C3-C5 cycloalkyl group);
  • L3 exists or does not exist, when L3 exists, selected from o an integer selected from 1-10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10);
  • the 1- or 2-position chiral carbon atom has two kinds of chirality: R absolute configuration or S absolute configuration;
  • n is selected from 0 or 1.
  • the linker-drug compound or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: the Ac has the structure shown in the following formula B,
  • Z is non-limitingly selected from the group consisting of one or more of hydrophilic structure carboxyl, phosphoric acid, polyphosphoric acid, phosphorous acid, sulfonic acid, sulfinic acid or polyethylene glycol (PEG);
  • Y' is an optional bracket connecting the amino group and Z; preferably Y' is C1-C6 alkylene (such as methylene);
  • the linker-drug compound or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: the Ac is non-limitingly selected from glycine, ( D/L) Alanine, (D/L) Leucine, (D/L) Isoleucine, (D/L) Valine, (D/L) Phenylalanine, (D/L) ) proline, (D/L) tryptophan, (D/L) serine, (D/L) tyrosine, (D/L) cysteine, (D/L) cystine, ( D/L) Arginine, (D/L) Histidine, (D/L) Methionine, (D/L) Asparagine, (D/L) Glutamine, (D/L) Threonine , (D/L) aspartic acid, (D/L) glutamic acid, natural or unnatural amino acid derivatives or the following structures,
  • the linker-drug compound or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that Ac is non-limitingly selected from glycine, phosphoric acid, ( D/L) Glutamic acid or polyethylene glycol hydrophilic structure.
  • the linker-drug compound or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in that: the linker-drug compound is non-limitingly selected from From the following structure or its isomers,
  • o is selected from an integer of 1-10 (for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • linker-drug compound disclosed in the third aspect of the present invention or its pharmaceutically acceptable salt or solvate can be used as an intermediate for coupling with the ligand Ab to form the formula I described in the first aspect and the second aspect Or the ligand-camptothecin derivative conjugate of formula II.
  • the fourth aspect of the present invention discloses a ligand-camptothecin derivative conjugate or its pharmaceutically acceptable preparation as described in the first aspect and the second aspect, shown in the general formula I or II.
  • the method of salt or solvate characterized in that: comprising the following steps,
  • 1-position, 2-position or 3-position chiral carbon atom has absolute chirality of R configuration or S configuration
  • the present application also relates to the linker-drug compound disclosed in the third aspect or its pharmaceutically acceptable salt or solvate as an intermediate in the preparation of ligand-camptothecin derivative conjugate or its pharmaceutically acceptable Use in salts or solvates.
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is the ligand- A camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof.
  • the preparation is carried out according to the preparation method disclosed in the fourth aspect.
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 6.4 is a bispecific antibody or antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 4 is a bispecific antibody or an antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 22 is a bispecific antibody or antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 24 is a bispecific antibody or antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 25 is a bispecific antibody or an antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or a pharmaceutically acceptable salt or solvate thereof is disclosed, characterized in In that: the ligand-camptothecin derivative conjugates or pharmaceutically acceptable salts or solvates thereof are non-limitingly selected from the following structures or their succinimide ring-opened structures or their isomers,
  • SI-1 ⁇ 26 is a bispecific antibody or an antigen-binding fragment thereof targeting both EGFR and HER3;
  • n is selected from an integer of 1-10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).
  • the ligand-camptothecin derivative conjugate or its pharmaceutically acceptable salt or solvate or linker is disclosed -
  • the drug compound or its pharmaceutically acceptable salt or solvate characterized in that: the pharmaceutically acceptable salt includes sodium salt, potassium salt, calcium salt or magnesium salt formed with the acidic functional group in the structural formula and Acetate, trifluoroacetate, citrate, oxalate, tartrate, malate, nitrate, chloride, bromide, iodide, sulfate, bisulfate, phosphoric acid formed by basic functional groups Salt, lactate, oleate, ascorbate, salicylate, formate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate or p-toluenesulfonate.
  • the fifth aspect of the present invention discloses a pharmaceutical composition, which comprises the ligand-camptothecin derivative conjugate described in the first aspect, the second aspect or a pharmaceutically acceptable salt or solvate thereof, or the third aspect
  • the sixth aspect of the present invention discloses a pharmaceutical preparation, which comprises the ligand-camptothecin derivative conjugate described in the first aspect, the second aspect or a pharmaceutically acceptable salt or solvate thereof, or the third aspect The linker-drug compound or a pharmaceutically acceptable salt or solvate thereof.
  • the seventh aspect of the present invention discloses the ligand-camptothecin derivative conjugate described in the first aspect, the second aspect or a pharmaceutically acceptable salt or solvate thereof, or the linker-drug described in the third aspect Use of the compound or its pharmaceutically acceptable salt or solvate, or the pharmaceutical composition described in the fifth aspect and/or the pharmaceutical preparation described in the sixth aspect, in the preparation of a medicament for treating or preventing cancer or tumor ;
  • the cancer or tumor expresses EGFR and/or HER3;
  • the cancer or tumor is selected from adenocarcinoma, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, lung cancer, Colon cancer, rectal cancer, colorectal cancer, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, melanoma, glioma, neuroblastoma, glioma multiforme, sarcoma, lymphoma and leukemia Solid or hematological tumors.
  • the eighth aspect of the present invention discloses a method for treating or preventing cancer or tumors, comprising administering a preventive or therapeutically effective amount of the ligand-camptothecin derivative described in the first aspect or the second aspect to a subject in need thereof.
  • the cancer or tumor expresses EGFR and/or HER3;
  • the cancer or tumor is selected from adenocarcinoma, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, lung cancer, Colon cancer, rectal cancer, colorectal cancer, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, melanoma, glioma, neuroblastoma, glioma multiforme, sarcoma, lymphoma and leukemia Solid or hematological tumors.
  • C1-C6 alkyl and “C1-C6” in various composite groups involving “C1-C6 alkyl” (for example, “substituted C1-C6 alkyl”, “deuterated C1-C6 alkyl")
  • Alkyl can be replaced with "C1-C20 alkyl", “C1-C12 alkyl” or "C1-C10 alkyl”;
  • C3-C8 cycloalkyl and “C3-C8 cycloalkyl” in various composite groups involving “C3-C8 cycloalkyl” can be replaced by "C3-C20 cycloalkyl” or "C3-C10 cycloalkyl”;
  • C1-C6 alkoxy and “C1-C6 alkoxy” in various complex groups related to it can be replaced by "C1-C20 alkoxy", “C1-C12 alkoxy” or "C1 -C10 alkoxy”;
  • the EGFR/Her3 bispecific antibody-drug conjugate provided by the present invention is a bispecific antibody ADC targeting EGFR/Her3 dual targets at the same time, which has good molecular stability and good preclinical efficacy. It has excellent clinical therapeutic effect.
  • Figure 1A illustrates SEC-HPLC detection of ADC-5 aggregation.
  • Figure 1B illustrates SEC-HPLC detection of ADC-6 aggregation.
  • Figure 1C illustrates SEC-HPLC detection of ADC-64 aggregation.
  • Figure 1D illustrates SEC-HPLC detection of ADC-DS aggregation.
  • Figure 1E illustrates SEC-HPLC detection of ADC-108 aggregation.
  • Figure 1F illustrates SEC-HPLC detection of ADC-112 aggregation.
  • Figure 1G illustrates SEC-HPLC detection of ADC-215 aggregation.
  • Figure 1H illustrates SEC-HPLC detection of ADC-219 aggregation.
  • Figure 1I illustrates SEC-HPLC detection of ADC-227 aggregation.
  • Figure 1J illustrates SEC-HPLC detection of ADC-235 aggregation.
  • FIG. 2A illustrates RP-HPLC detection of ADC-5 drug-antibody conjugation ratio (DAR).
  • Figure 2B illustrates the detection of ADC-6 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • DAR drug-antibody conjugation ratio
  • FIG. 2C illustrates RP-HPLC detection of ADC-10 drug-antibody conjugation ratio (DAR).
  • Figure 2D illustrates the detection of ADC-12 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • FIG. 2E illustrates RP-HPLC detection of ADC-64 drug-antibody conjugation ratio (DAR).
  • Figure 2F illustrates RP-HPLC detection of ADC-108 drug-antibody conjugation ratio (DAR).
  • Figure 2G illustrates the detection of ADC-112 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • DAR drug-antibody conjugation ratio
  • Figure 2H illustrates the detection of ADC-215 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • DAR drug-antibody conjugation ratio
  • Figure 2I illustrates the detection of ADC-219 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • Figure 2J illustrates RP-HPLC detection of ADC-227 drug-antibody conjugation ratio (DAR).
  • Figure 2K illustrates RP-HPLC detection of ADC-235 drug-antibody conjugation ratio (DAR).
  • Figure 2L illustrates the detection of ADC-243 drug-antibody conjugation ratio (DAR) by RP-HPLC.
  • DAR drug-antibody conjugation ratio
  • FIG. 3A illustrates that ADC-112 and SI-1 ⁇ 4 antibodies maintain affinity for both antigens EGFR and HER3-Fc.
  • Figure 3B illustrates that ADC-6 and SI-1 x 6.4 antibodies maintain affinity for both antigens EGFR and HER3-Fc.
  • FIG. 3C illustrates that ADC-219 and SI-1 ⁇ 22 antibody maintain affinity for both antigens EGFR and HER3-Fc.
  • FIG. 3D illustrates that ADC-227 and SI-1 ⁇ 24 antibody maintain affinity for both antigens EGFR and HER3-Fc.
  • Figure 3E illustrates that ADC-235 and SI-1 ⁇ 25 antibody maintain affinity for both antigens EGFR and HER3-Fc.
  • FIG. 3F illustrates that ADC-243 and SI-1 ⁇ 26 antibody maintain affinity for both antigens EGFR and HER3-Fc.
  • Figure 4A illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in A431.
  • Figure 4B illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in BXPC-3.
  • Figure 4C illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in FaDu.
  • Figure 4D illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in HARA-B.
  • Figure 4E illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in HCC827.
  • Figure 4F illustrates the in vitro efficacy of 6 naked antibodies and 6 ADCs in SW620.
  • Fig. 5A illustrates the results of in vivo pharmacodynamic experiments of ADC-6 and SI-1 ⁇ 6.4 naked antibody in A431 single tumor model.
  • Figure 5B illustrates the results of in vivo drug efficacy experiments of ADC-6, SI-1 ⁇ 6.4 naked antibody, Cetuximab (Cet), and ADC-214 in SW620 single tumor model.
  • Figure 5C illustrates the results of in vivo drug efficacy experiments of ADC-6 and SI-1 ⁇ 6.4 naked antibody in A431+SW620 heterogeneous tumors.
  • FIG. 6A illustrates the results of in vivo drug efficacy experiments of ADC-6, ADC-219, ADC-235, ADC-227, and ADC-112 in the A431 single tumor model.
  • Figure 6B illustrates the results of in vivo drug efficacy experiments of ADC-6, ADC-219, ADC-235, ADC-227, and ADC-112 in the BXPC-3 single tumor model.
  • FIG. 7A illustrates the in vitro drug effects of SI-1 ⁇ 6.4, Cetuximab, ADC-6, ADC-214, and d3 on human poorly differentiated lung cancer squamous cell line Oka-c-1.
  • FIG. 7B illustrates the in vitro drug effects of SI-1 ⁇ 6.4, Cetuximab, ADC-6, ADC-214, and d3 on human lung squamous cell carcinoma SK-MES-1.
  • ligand is a macromolecular compound that can recognize and bind to an antigen or receptor associated with a target cell.
  • the role of the ligand is to present the drug to the target cell population to which the ligand is bound, including but not limited to protein hormones, lectins, growth factors, antibodies or other molecules capable of binding to cells.
  • the ligand is expressed as Ab, and the ligand can form a linkage with the linking unit through a heteroatom on the ligand, preferably an antibody or an antigen-binding fragment thereof, and the antibody is selected from chimeric antibodies, human Antibodies, fully human or murine antibodies; preferably monoclonal antibodies.
  • a Ligand unit is a targeting agent that specifically binds to a target moiety.
  • the ligand is capable of specifically binding to a cellular component or to a cellular component or to other target molecules of interest.
  • the target moiety or target is usually on the cell surface.
  • the Ligand unit functions to deliver the Drug unit to the specific target cell population with which the Ligand unit interacts.
  • Ligands include, but are not limited to, proteins, polypeptides and peptides, as well as non-proteins such as sugars.
  • Suitable Ligand units include, for example, antibodies, such as full-length (intact) antibodies and antigen-binding fragments thereof.
  • the Ligand unit is a non-antibody targeting agent
  • it may be a peptide or polypeptide, or a non-proteinaceous molecule.
  • targeting agents include interferons, lymphokines, hormones, growth and colony stimulating factors, vitamins, nutrient transport molecules, or any other cell binding molecules or substances.
  • the linker is covalently attached to the sulfur atom of the ligand.
  • the sulfur atom is that of a cysteine residue, which forms an interchain disulfide bond of the antibody.
  • the sulfur atom is that of a cysteine residue that has been introduced into the Ligand unit, which forms an interchain disulfide bond of the antibody.
  • the sulfur atom is that of a cysteine residue that has been introduced into the Ligand unit (eg, by site-directed mutagenesis or chemical reaction).
  • the sulfur atom to which the linker binds is selected from cysteine residues that form interchain disulfide bonds of the antibody or cysteine residues that have been introduced into the Ligand unit (e.g., by site-directed mutagenesis or chemical reaction).
  • the EU according to the EU in Kabat ⁇ [Kabat E.A et al., (1991)] "Sequences of proteins of Immunological Interest", Fifth Edition, NIH Publication 91-3242 ⁇ Index numbering system.
  • an “antibody” or “antibody unit” includes within its scope any portion of an antibody structure. This unit can bind, reactively associate with, or complex a receptor, antigen or other receptor unit possessed by a population of targeted cells.
  • An antibody can be any protein or protein-like molecule that binds, complexes, or reacts with a portion of a cell population to be treated or bioengineered. The antibody constituting the antibody-drug conjugate in the present invention maintains the antigen-binding ability in its original wild state. Therefore, the antibodies of the present invention can specifically bind to antigens.
  • Antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, regulators of cell survival, regulators of cell proliferation, molecules associated with tissue growth and differentiation (such as known or predicted functional), lymphokines, cytokines, molecules involved in cell cycle regulation, molecules involved in angiogenesis, and molecules associated with angiogenesis (if known or predicted to be functional).
  • TAAs tumor-associated antigens
  • cell surface receptor proteins and other cell surface molecules regulators of cell survival, regulators of cell proliferation, molecules associated with tissue growth and differentiation (such as known or predicted functional), lymphokines, cytokines, molecules involved in cell cycle regulation, molecules involved in angiogenesis, and molecules associated with angiogenesis (if known or predicted to be functional).
  • Tumor-associated factors may be cluster differentiation factors (such as CD protein).
  • Antibodies for use in antibody drug conjugates include, but are not limited to, antibodies directed against cell surface receptors and tumor-associated antigens.
  • tumor-associated antigens are well known in the art, and can be prepared by well-known antibody production methods and information in the art.
  • targets can be specifically expressed on the surface of one or more cancer cells, while little or no expression is expressed on the surface of one or more non-cancer cells.
  • tumor-associated polypeptides are more overexpressed on the surface of cancer cells than on the surface of non-cancer cells.
  • tumor-associated factors could greatly improve the specific targeting properties of antibody-based therapies for cancer.
  • related information of antigens well-known in the industry are marked as follows, including names, other names, and gene bank accession numbers.
  • Nucleic acid and protein sequences corresponding to tumor-associated antigens can be found in public databases, such as Genbank.
  • Genbank The corresponding tumor-associated antigen targeted by the antibody includes all amino acid sequence variants and isotypes, and has at least 70%, 80%, 85%, 90% or 95% homology with the sequence confirmed in the reference, or has the same identity as the reference
  • the tumor-associated antigen sequences in the literature have completely consistent biological properties and characteristics.
  • inhibitor means to reduce by a detectable amount, or to prevent completely.
  • cancer refers to a physiological condition or disease characterized by unregulated cell growth.
  • Tumor includes cancer cells.
  • autoimmune disease is a disease or disorder arising from targeting an individual's own tissues or proteins.
  • cytotoxic drug refers to a cytotoxic drug, which is denoted as d, which is a chemical molecule that can strongly disrupt the normal growth of tumor cells.
  • cytotoxic drugs can kill tumor cells at a sufficiently high concentration, but due to lack of specificity, they can also cause apoptosis of normal cells while killing tumor cells, resulting in serious side effects.
  • the term includes toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, radioactive isotopes (e.g.
  • linker or "connecting fragment” or “linking unit” refers to a chemical structural fragment or bond that is connected to a ligand at one end and a drug at the other end, and can also be connected to other linkers before being connected to a drug.
  • Linkers including stretchers, spacers and amino acid units, can be synthesized by methods known in the art, such as described in US2005-0238649A1.
  • the linker can be a "cleavable linker" that facilitates release of the drug in the cell.
  • acid-labile e.g., hydrazone
  • protease-sensitive e.g., peptidase-sensitive
  • photolabile dimethyl, or disulfide-containing linkers
  • linkers or “linkers of antibody drug conjugates” as used herein can be divided into two categories: non-cleavable linkers and cleavable linkers.
  • the drug release mechanism is as follows: after the conjugate binds to the antigen and is endocytosed by the cell, the antibody is enzymatically hydrolyzed in the lysosome to release the small molecule drug, Linker, an active molecule composed of antibody amino acid residues. The resulting change in the molecular structure of the drug does not reduce its cytotoxicity, but since the active molecule is charged (amino acid residues), it cannot penetrate neighboring cells.
  • cleavable linkers are mainly divided into: chemical sensitive linkers and enzyme sensitive linkers. Chemosensitive linkers can be selectively cleaved due to differences in plasma and cytoplasmic or tumor microenvironmental properties. Such properties include pH, glutathione concentration, etc.
  • Linkers that are sensitive to pH are relatively stable in the neutral or slightly alkaline environment of blood (pH7.3-7.5), but in the weakly acidic tumor microenvironment (pH5.0-6.5) .5-5.0) will be hydrolyzed, such as hydrazones, carbonates, acetals, ketals. Due to the limited plasma stability of acid-cleavable linkers, antibody-drug conjugates based on such linkers usually have a short half-life (2-3 days). This short half-life limits the application of pH-sensitive linkers in the new generation of antibody-drug conjugates to some extent. Glutathione-sensitive linkers, also known as disulfide linkers.
  • Drug release is based on the difference between the high concentration of intracellular glutathione (millimolar range) and the relatively low concentration of glutathione in the blood (micromolar range). This is especially true for tumor cells, where low oxygen levels lead to increased reductase activity and thus higher glutathione concentrations. Disulfide bonds are thermodynamically stable, so they have good stability in plasma. Enzyme-labile linkers, such as peptide linkers, allow better control of drug release. Peptide linkers can be effectively cleaved by proteases in lysosomes, such as cathepsin B.
  • Enzyme-labile linkers are widely used as cleavable linkers for antibody-drug conjugates due to their high plasma stability and good intracellular cleavage selectivity and efficiency.
  • antibody-drug conjugate means that an antibody is linked to a biologically active drug through a stable linker unit.
  • ligand-drug conjugate is preferably an antibody-drug conjugate (antibody drug conjugate, ADC), which refers to linking a monoclonal antibody or antibody fragment with a toxic drug with biological activity through a stable linking unit. .
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms (i.e. "C1-C20 alkyl”), preferably an alkane group containing 1 to 12 carbon atoms (i.e. "C1-C12 alkyl”), more preferably an alkyl group containing 1 to 10 carbon atoms (i.e. "C1-C10 alkyl”), most preferably an alkyl group containing 1 to 6 carbon atoms (i.e. " C1-C6 alkyl”).
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl group, 2,3-dimethylbutyl group, etc.
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo.
  • R', R" and R"' each independently refers to hydrogen, unsubstituted C 1-8 alkyl, unsubstituted C6-C12 aryl (or C6-C10 aryl), C6-C12 aryl substituted by 1-3 halogen (or C6-C10 aryl), unsubstituted C 1-8 alkyl, C 1-8 alkoxy or C 1-8 thioalkoxy, or unsubstituted C6-C12 aryl ( or C6- C10 aryl) -C1-4 alkyl.
  • R' and R" When R' and R" are connected to the same nitrogen atom, they can form a 3-, 4-, 5-, 6- or 7-membered ring together with the nitrogen atom.
  • -NR'R" includes 1-pyrrolidinyl and 4-morpholinyl.
  • alkylene refers to a saturated straight or branched chain aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane by removing two hydrogen atoms, which are A linear or branched chain group containing 1 to 20 carbon atoms, preferably an alkylene group containing 1 to 12 carbon atoms, more preferably an alkylene group containing 1 to 6 carbon atoms.
  • Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH 2 -, 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene ( -CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), 1,5-butylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -), etc.
  • the alkylene group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably independently optionally selected from the group consisting of alkyl, alkenyl, alkyne radical, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy One or more substituents in radical, cycloalkylthio, heterocycloalkylthio and oxo.
  • alkoxy refers to -O-(alkyl) and -O-(cycloalkyl), wherein alkyl or cycloalkyl is as defined above.
  • C1-C6 alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring contains 3 to 20 carbon atoms (ie “C3-C20 cycloalkyl”), preferably contains 3 to 12 carbon atoms (i.e. "C3-C12 cycloalkyl”), more preferably 3 to 10 carbon atoms (i.e. "C3-C10 cycloalkyl”), most preferably 3 to 8 carbon atoms (i.e. "C3 -C8 cycloalkyl”).
  • Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexyl Dienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes spiro, fused and bridged cycloalkyl.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms (i.e. "3-20 membered heterocyclyl”), wherein one or more ring Atoms are heteroatoms selected from nitrogen, oxygen, or S(O) m (where m is an integer from 0 to 2), excluding ring portions of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • the cycloalkyl ring contains 3 to 12 ring atoms (ie, "3-12 membered heterocyclyl"), of which 1 to 4 are heteroatoms; more preferably, the cycloalkyl ring contains 3 to 10 ring atoms (ie, "3-10 membered heterocyclyl") heterocyclyl").
  • monocyclic heterocyclyl eg, 3-7 membered heterocyclyl
  • Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls.
  • cycloalkylalkyl refers to an alkyl group substituted by one or more cycloalkyl groups, preferably by one cycloalkyl group, wherein alkyl is as defined above, and wherein cycloalkyl is as defined above. For example, C3-C8cycloalkylC1-C6alkyl.
  • haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above. For example, halogenated C1-C6 alkyl.
  • deuteroalkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above. For example, deuterated C1-C6 alkyl.
  • C6-C12 aryl refers to a group of a carbocyclic aromatic system having 6-12 carbon atoms.
  • C6-C10 aryl refers to a carbocyclic aromatic system group having 6-10 carbon atoms, such as phenyl, naphthyl and the like.
  • heteroaryl refers to an aromatic heterocycle, usually 5-, 6-, 7-, 8-, 9-, with 1 to 3 heteroatoms selected from N, O or S , 10-membered heterocyclic rings; heteroaryl rings can optionally be further fused or attached to aromatic and non-aromatic carbocyclic and heterocyclic rings.
  • Non-limiting examples of said 5-10 membered heteroaryl are, for example, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, thiaxazolyl, Pyrrolyl, phenyl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzofuryl, benzothienyl, benzo 1,3- Dioxolane (benzodioxol), isoindolinyl, benzimidazolyl, indazolyl, quinolinyl, isoquinolyl, 1,2,3-triazolyl, 1-benzene Base-1,2,3-triazolyl, 2,3-dihydroindolyl, 2,3-dihydrobenzofuryl, 2,3
  • R', R" and R"' each independently refer to Hydrogen, unsubstituted C 1-8 alkyl, unsubstituted C6-C12 aryl (or C6-C10 aryl), C6-C12 aryl (or C6-C10 aryl) substituted by 1-3 halogen ), unsubstituted C 1-8 alkyl, C 1-8 alkoxy or C 1-8 thioalkoxy, or unsubstituted C6-C12 aryl (or C6-C10 aryl)-C 1 - 4 alkyl groups.
  • R' and R" When R' and R" are attached to the same nitrogen atom, they can form a 3-, 4-, 5-, 6- or 7-membered ring together with the nitrogen atom.
  • -NR'R" includes 1-pyrrolidinyl and 4-morpholinyl.
  • hydroxyl refers to a -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH2 .
  • nitro refers to -NO2 .
  • amido refers to -C(O)N(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
  • carboxylate refers to -C(O)O(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
  • the invention also includes the various deuterated forms of Formula I.
  • Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom.
  • Those skilled in the art can refer to the relevant literature to synthesize the deuterated form of Formula I.
  • Commercially available deuterated starting materials may be used in the preparation of deuterated forms of Formula I, or they may be synthesized using conventional techniques using deuterated reagents, non-limiting examples of which include: deuterated borane, trideuterated Borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
  • antibody refers to an immunoglobulin, which is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains linked by interchain disulfide bonds.
  • the amino acid composition and sequence of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different.
  • immunoglobulins can be divided into five classes, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are ⁇ , ⁇ , and ⁇ chains, respectively. , ⁇ chain and ⁇ chain.
  • IgG can be divided into different subclasses according to the amino acid composition of its hinge region and the number and position of heavy chain disulfide bonds.
  • IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
  • Light chains are classified as either kappa chains or lambda chains by difference in the constant region.
  • Each of the five Ig classes can have either a kappa chain or a lambda chain.
  • the antibody described in the present invention is preferably a specific antibody directed at a cell surface antigen on a target cell, and non-limiting examples are the following antibodies: anti-EGFRvIII antibody, anti-DLL-3 antibody, anti-PSMA antibody, anti-CD70 antibody, anti-MUC16 antibody , anti-ENPP3 antibody, anti-TDGF1 antibody, anti-ETBR antibody, anti-MSLN antibody, anti-TIM-1 antibody, anti-LRRC15 antibody, anti-LIV-1 antibody, anti-CanAg/AFP antibody, anti-cladin 18.2 antibody, anti-Mesothelin antibody, anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-c-MET antibody, anti-SLITRK6 antibody, anti-KIT/CD117 antibody, anti-STEAP1 antibody, anti-SLAMF7/CS1 antibody, anti-NaPi2B/SLC34A2 antibody, anti-GPNMB antibody, anti-HER3(ErbB3) Antibody, anti-MUC1/CD227 antibody, anti
  • solvate or “solvate” means that the ligand-drug conjugate of the present invention forms a pharmaceutically acceptable solvate with one or more solvent molecules, non-limiting examples of which include water, ethanol, acetonitrile , isopropanol, DMSO, ethyl acetate.
  • drug loading refers to the average amount of cytotoxic drugs loaded on each antibody in Formula I, and can also be expressed as the ratio of the amount of drug to the amount of antibody.
  • the range of drug loading can be that each antibody (Ab) is linked to 0 - 12, preferably 1-10 cytotoxic drugs (D).
  • the drug loading amount is expressed as n, which may be an exemplary average value of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
  • the average amount of drug product per ADC molecule after conjugation can be characterized by conventional methods such as UV/visible spectroscopy, mass spectrometry, ELISA assay and HPLC.
  • the cytotoxic drug is coupled to the cysteine sulfhydryl-SH opened between the antibody chains and/or the sulfhydryl-SH of the cysteine residue for site-directed mutation through a linking unit.
  • the number of drug molecules that can be coupled to the antibody in the conjugation reaction will be less than or equal to the theoretical maximum.
  • the loading of ligand cytotoxic drug conjugates can be controlled by the following non-limiting methods, including:
  • pharmaceutically acceptable salt refers to a salt of the ligand-drug conjugate of the present invention, or a salt of a compound described in the present invention, when such salt is used in a mammal It has safety and efficacy, and has proper biological activity.
  • the ligand-drug conjugate compound of the present invention contains at least one carboxyl group, so it can form a salt with a base.
  • pharmaceutically acceptable salts include: sodium salt, potassium salt, calcium salt or magnesium salt, etc.
  • pharmaceutically acceptable salt refers to a salt of the antibody-drug conjugate of the present invention, or a salt of a compound described in the present invention, which has Safety and effectiveness, and have appropriate biological activity, the ligand-drug conjugate compound of the present invention contains at least one amino group, so it can form salts with acids
  • pharmaceutically acceptable salts include: hydrochloric acid Salt, hydrobromide, hydroiodide, sulfate, hydrogensulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, perulate, hydrogenphosphate, phosphoric acid Dihydrogen salt, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate , p-toluenesulfonate.
  • Acidic amino acid means that the isoelectric point of amino acid is less than 7. Acidic amino acid molecules often have one or more acidic groups such as carboxyl groups, which can be effectively ionized into negative ions in the structure to increase hydrophilicity. Acidic amino acids may be natural or unnatural amino acids.
  • Natural amino acid refers to an amino acid that is biosynthesized. Natural amino acids are generally L-form, but there are a few exceptions, such as glycine, including natural and biosynthetic.
  • Unnatural amino acid refers to an amino acid obtained by synthetic means.
  • reaction solution 1 15a (5g, 9.95mmol) and 15mL DMF into a 50mL single-necked bottle, after dissolving, add DBU (1.68g, 11mmol) in an ice-water bath, react for 1h, and record it as the reaction solution 1;
  • reaction solution 1 20a (4g, 7.6mmol) and 10mL DMF into a 50mL single-necked bottle. After dissolving, add DBU (1.39g, 9.1mmol) in an ice-water bath, react for 1h, and record it as the reaction solution 1;
  • Step 4 Compounds 20e-1 and 20e-2
  • the third step compound SM5 (refer to literature Org.Lett., 2006, 8, 3387-3390.)
  • Embodiment 47 (comparative example)
  • Compound 45 was synthesized by referring to the method provided in Example 58 of the patent "CN104755494A”.
  • Step 1 Compounds 50a and 50b
  • the first step compound 51a and compound 51b
  • Step 1 Compounds 54a and 54b
  • Step 1 Compounds 55a and 55b
  • the first step the synthesis of compound 58a
  • Step 1 Compounds 65a and 65b

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2022/132027 2021-11-15 2022-11-15 双特异性抗体-喜树碱类药物偶联物及其医药用途 Ceased WO2023083381A1 (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2022386505A AU2022386505A1 (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
JP2024529137A JP7767613B2 (ja) 2021-11-15 2022-11-15 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
PE2024001076A PE20250759A1 (es) 2021-11-15 2022-11-15 Conjugado de anticuerpo bispecifico-farmaco de camptotecina y uso farmaceutico de este
CA3237844A CA3237844A1 (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
IL312694A IL312694A (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US18/710,044 US20250059296A1 (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
KR1020247019719A KR20240101682A9 (ko) 2021-11-15 2022-11-15 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
MX2024005831A MX2024005831A (es) 2021-11-15 2022-11-15 Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
EP22892173.0A EP4434548A1 (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
TW112128599A TW202434301A (zh) 2021-11-15 2023-07-31 雙特異性抗體－喜樹鹼類藥物偶聯物及其醫藥用途
CONC2024/0006160A CO2024006160A2 (es) 2021-11-15 2024-05-15 Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
US18/957,324 US12577325B2 (en) 2021-11-15 2024-11-22 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
JP2025182282A JP2026035591A (ja) 2021-11-15 2025-10-29 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111351599.X 2021-11-15
CN202111351599 2021-11-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US18/710,044 A-371-Of-International US20250059296A1 (en) 2021-11-15 2022-11-15 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US18/957,324 Continuation US12577325B2 (en) 2021-11-15 2024-11-22 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
WO2023083381A1 true WO2023083381A1 (zh) 2023-05-19

Family

ID=86306961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/132027 Ceased WO2023083381A1 (zh) 2021-11-15 2022-11-15 双特异性抗体-喜树碱类药物偶联物及其医药用途

Country Status (14)

Country Link
US (2) US20250059296A1 (https=)
EP (1) EP4434548A1 (https=)
JP (2) JP7767613B2 (https=)
KR (1) KR20240101682A9 (https=)
CN (1) CN116120460A (https=)
AU (1) AU2022386505A1 (https=)
CA (1) CA3237844A1 (https=)
CL (2) CL2024001450A1 (https=)
CO (1) CO2024006160A2 (https=)
IL (1) IL312694A (https=)
MX (1) MX2024005831A (https=)
PE (1) PE20250759A1 (https=)
TW (1) TW202434301A (https=)
WO (1) WO2023083381A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025016453A1 (zh) 2023-07-19 2025-01-23 映恩生物制药（苏州）有限公司 一种双特异性抗体、其药物偶联物及其用途
WO2025040165A1 (zh) * 2023-08-23 2025-02-27 成都精西药业有限责任公司 一种连接子-药物的制备方法
WO2025085303A1 (en) * 2023-10-18 2025-04-24 Systimmune, Inc. Methods and compositions for treating tumors using antibody camptothecin drug conjugates
WO2025128837A1 (en) * 2023-12-13 2025-06-19 Systimmune, Inc. Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061256A2 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Egfr binding complex and method of making and using thereof
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025131063A1 (en) * 2023-12-22 2025-06-26 Fortvita Biologics Inc. Antibody drug conjugates targeting b7-h3 and trop2 and the use thereof
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0737683A1 (en) 1991-02-27 1996-10-16 Pfizer Inc. N-2-(Phthalimido)ethyl trans-piperidine-2,5-dicarboxylates as intermediates in the preparation of perhydro-1H-pyrido[1,2-a]pyrazines
US20050020645A1 (en) 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
CN104755494A (zh) 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
WO2015123679A1 (en) * 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
WO2016106157A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of makiing and using thereof
US20170035906A1 (en) * 2014-04-10 2017-02-09 Daiichi Sankyo Company, Limited (anti-her2 antibody)-drug conjugate
CN108452321A (zh) 2017-06-19 2018-08-28 四川百利药业有限责任公司 一种带酸性自稳定接头的抗体-药物偶联物
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2020063673A1 (zh) 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
WO2020244657A1 (zh) 2019-06-06 2020-12-10 上海翰森生物医药科技有限公司 抗b7-h4抗体-药物偶联物及其医药用途
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CN113827736A (zh) * 2020-06-08 2021-12-24 四川百利药业有限责任公司 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
CN113943310A (zh) * 2020-10-12 2022-01-18 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO2005056606A2 (en) 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
NZ596711A (en) 2009-05-01 2013-11-29 Dual variable domain immunoglobulins and uses thereof
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2678359A4 (en) 2011-02-24 2015-01-28 Merrimack Pharmaceuticals Inc COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM
SG192775A1 (en) 2011-03-15 2013-09-30 Merrimack Pharmaceuticals Inc Overcoming resistance to erbb pathway inhibitors
BR112014016299A8 (pt) 2011-12-30 2017-07-04 Abbvie Inc imunoglobulinas de domínio variável e usos das mesmas
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CA2873111A1 (en) 2012-05-11 2013-11-14 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US20150239977A1 (en) 2012-09-27 2015-08-27 Massachusetts Institute Of Technology Cd20- and egfr-binding proteins with enhanced stability
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA3081073C (en) 2013-03-12 2023-09-12 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
AU2014227638A1 (en) 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
LT3424955T (lt) 2013-12-25 2025-06-25 Daiichi Sankyo Company, Limited Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
SI3466976T1 (sl) 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
CN106470697B (zh) 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
CN105820248A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
KR101770559B1 (ko) 2015-04-23 2017-08-24 신일제약주식회사 EGFR에 특이적으로 결합하는 Fab 단편
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
WO2016210447A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US20170247458A1 (en) 2016-01-10 2017-08-31 Sorrento Therapeutics, Inc. Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112019011794A2 (pt) 2016-12-12 2019-10-29 Daiichi Sankyo Co Ltd composição farmacêutica, e, método terapêutico.
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
GB201705686D0 (en) 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN108948195B (zh) 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN108948206B (zh) 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
JP2020521759A (ja) 2017-05-26 2020-07-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
EP3638700B8 (en) 2017-06-14 2024-09-04 Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation Proteinaceous heterodimer and use thereof
CN109306010B (zh) 2017-07-26 2022-07-19 石家庄以岭药业股份有限公司 表皮生长因子受体抗体及其用途
AU2018318698A1 (en) 2017-08-16 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
EP3457139A1 (en) 2017-09-19 2019-03-20 Promise Advanced Proteomics Antibody-like peptides for quantifying therapeutic antibodies
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
CN108220244A (zh) 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
US12168691B2 (en) 2018-05-31 2024-12-17 Board Of Regents, The University Of Texas System VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
EP3810624A4 (en) 2018-06-22 2022-07-06 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
EP3866924A4 (en) 2018-06-29 2022-07-06 Krystal Biotech, Inc. COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CA3118397A1 (en) 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
CN111196855B (zh) 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
WO2020113164A1 (en) 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
WO2020118605A1 (zh) 2018-12-13 2020-06-18 丁邦 抗体-肿瘤坏死因子α融合蛋白及其制法和应用
EP3898681A2 (en) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
JP7506607B2 (ja) 2018-12-28 2024-06-26 協和キリン株式会社 ＴｆＲに結合するバイスペシフィック抗体
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN110256583B (zh) 2019-07-11 2022-05-20 中国科学院生物物理研究所 一种il-2突变体与抗体的融合蛋白及其应用
US12168690B2 (en) 2019-07-26 2024-12-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody
CN110669132B (zh) 2019-08-19 2023-03-31 天津大学前沿技术研究院 一种提高IgG1抗体产量的方法
CN114616031A (zh) 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
AU2020410460A1 (en) 2019-12-16 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof
MX2022008474A (es) 2020-01-22 2022-08-02 Jiangsu Hengrui Medicine Co Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
CN115485300A (zh) 2020-02-26 2022-12-16 索伦托药业有限公司 具有通用掩蔽部分的可活化的抗原结合蛋白
CN113388631B (zh) 2020-03-12 2022-08-09 天津大学 一种高产IgG1的重组菌及构建方法
CN115298220B (zh) 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
CA3177279A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
JP7689979B2 (ja) 2020-03-25 2025-06-09 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体を含む医薬組成物及びその使用
BR112022019042A2 (pt) 2020-03-25 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Método de preparação para conjugado anticorpo-fármaco
WO2021190586A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN115279781B (zh) 2020-03-26 2025-05-09 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
US10994021B1 (en) 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754771A (zh) 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN111848806B (zh) 2020-06-18 2022-06-10 广东安普泽生物医药股份有限公司 Egfr-cd3双功能抗体及其应用
MX2023001163A (es) 2020-07-27 2023-02-22 Tuojie Biotech Shanghai Co Ltd Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
JP7780953B2 (ja) 2020-09-15 2025-12-05 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン類医薬品及びその抗体複合体
KR20230079096A (ko) 2020-09-30 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도
US20250276078A1 (en) * 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
CN116133694B (zh) 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
WO2022099762A1 (zh) 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
CN114569739A (zh) 2020-12-01 2022-06-03 正大天晴药业集团股份有限公司 抗体药物偶联物
KR20250120438A (ko) 2021-02-05 2025-08-08 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
WO2022166719A1 (zh) 2021-02-08 2022-08-11 四川百利药业有限责任公司 一种ca4衍生物及其配体-药物偶联物
TW202300148A (zh) 2021-03-17 2023-01-01 大陸商江蘇恒瑞醫藥股份有限公司 喜樹鹼衍生物的製備方法
CN115192732B (zh) 2021-04-01 2025-02-18 成都百利多特生物药业有限责任公司 一种dna毒性二聚体化合物及其偶联物
US20240269307A1 (en) 2021-04-26 2024-08-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
BR112023023276A2 (pt) 2021-05-07 2024-01-30 Alx Oncology Inc Derivados de exatecan e conjugados anticorpo-fármaco destes
CA3224741A1 (en) 2021-06-25 2022-12-29 Coherent Biopharma (Suzhou), Limited Ligand-drug conjugate and use thereof
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
CN118139891A (zh) 2021-09-23 2024-06-04 上海翰森生物医药科技有限公司 抗体药物偶联物及其制备方法和医药用途
CN115850291B (zh) 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022389555A1 (en) 2021-11-17 2024-07-04 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate and use thereof
CN116212044A (zh) 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN118414339A (zh) 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
CN118450907A (zh) 2021-12-28 2024-08-06 百济神州有限公司 抗体药物结合物

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0737683A1 (en) 1991-02-27 1996-10-16 Pfizer Inc. N-2-(Phthalimido)ethyl trans-piperidine-2,5-dicarboxylates as intermediates in the preparation of perhydro-1H-pyrido[1,2-a]pyrazines
US20050020645A1 (en) 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
CN104755494A (zh) 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
WO2015123679A1 (en) * 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
US20170035906A1 (en) * 2014-04-10 2017-02-09 Daiichi Sankyo Company, Limited (anti-her2 antibody)-drug conjugate
WO2016106158A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
WO2016106157A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of makiing and using thereof
CN108452321A (zh) 2017-06-19 2018-08-28 四川百利药业有限责任公司 一种带酸性自稳定接头的抗体-药物偶联物
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
WO2020063673A1 (zh) 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
WO2020244657A1 (zh) 2019-06-06 2020-12-10 上海翰森生物医药科技有限公司 抗b7-h4抗体-药物偶联物及其医药用途
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CN113827736A (zh) * 2020-06-08 2021-12-24 四川百利药业有限责任公司 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
CN113943310A (zh) * 2020-10-12 2022-01-18 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131
CHEMICAL COMMUNICATIONS, vol. 55, no. 53, 2019, pages 7699 - 7702
DUCRY ET AL., BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13
J. BOIL. CHEM., vol. 243, 1968, pages 3558
JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 13, 2013, pages 5541 - 5552
KABAT E.A ET AL.: "NIH Publication", vol. 91, 1991, article "Sequences of proteins of Immunological Interest", pages: 3242
NATURE COMMUNICATIONS, vol. 11, no. 1, 2020, pages 56
ORG. LETT., vol. 8, 2006, pages 3387 - 3390

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025016453A1 (zh) 2023-07-19 2025-01-23 映恩生物制药（苏州）有限公司 一种双特异性抗体、其药物偶联物及其用途
WO2025040165A1 (zh) * 2023-08-23 2025-02-27 成都精西药业有限责任公司 一种连接子-药物的制备方法
WO2025085303A1 (en) * 2023-10-18 2025-04-24 Systimmune, Inc. Methods and compositions for treating tumors using antibody camptothecin drug conjugates
WO2025128837A1 (en) * 2023-12-13 2025-06-19 Systimmune, Inc. Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP4434548A1 (en) 2024-09-25
CN116120460A (zh) 2023-05-16
US12577325B2 (en) 2026-03-17
CL2024001450A1 (es) 2024-08-30
JP2024543508A (ja) 2024-11-21
CL2026000307A1 (es) 2026-03-20
KR20240101682A9 (ko) 2025-12-10
US20250059296A1 (en) 2025-02-20
MX2024005831A (es) 2024-07-09
IL312694A (en) 2024-07-01
CO2024006160A2 (es) 2024-08-08
KR20240101682A (ko) 2024-07-02
PE20250759A1 (es) 2025-03-13
CA3237844A1 (en) 2023-05-19
JP7767613B2 (ja) 2025-11-11
JP2026035591A (ja) 2026-03-04
AU2022386505A1 (en) 2024-05-23
TW202434301A (zh) 2024-09-01
US20250115679A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
WO2023083381A1 (zh) 双特异性抗体-喜树碱类药物偶联物及其医药用途
JP7686677B2 (ja) 高安定性の親水性結合ユニットを有するカンプトテシン類薬物及びその複合体
CN106604927B (zh) 细胞毒性苯并二氮杂䓬衍生物
WO2024140450A1 (zh) N-烷氧烷基取代的喜树碱衍生物的抗体偶联药物
WO2023098889A1 (zh) 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN114409562B (zh) 一种ca4衍生物及其配体-药物偶联物
TW202304920A (zh) 一種dna毒性二聚體化合物及其偶聯物
HK40094423A (zh) 双特异性抗体-喜树碱类药物偶联物及其医药用途
HK40094591A (zh) 抗人trop2抗体-喜树碱类药物偶联物及其医药用途
WO2024067477A1 (zh) 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
JP7667870B2 (ja) Ｄｎａ毒性二量体及びその複合体
WO2025128837A1 (en) Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN120860241A (zh) 抗人dll3抗体-喜树碱类药物偶联物及其医药用途
HK40116345A (en) Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN121422246A (zh) 抗人ror1抗体-药物偶联物及其用途
HK40083545A (en) Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
KR20250133813A (ko) Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22892173

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3237844

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12024551128

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2024529137

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202417037809

Country of ref document: IN

Ref document number: 001076-2024

Country of ref document: PE

Ref document number: 2401003092

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: NC2024/0006160

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024009231

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022386505

Country of ref document: AU

Date of ref document: 20221115

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2024000584

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020247019719

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2022892173

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022892173

Country of ref document: EP

Effective date: 20240617

WWE Wipo information: entry into national phase

Ref document number: 11202403121R

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: NC2024/0006160

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112024009231

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240509